Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined COVID-19 and influenza vaccine in adults 50+
NCT06237049Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tozinameran in coronavirus disease 2019 (COVID-19) and influenza (4 arms), sponsored by Pfizer. Primary endpoints: Percentage of Participants Who Reported Any Local Reaction up to 7 Days Following Vaccination, Percentage of Participants Who Reported Any Systemic Events up to 7 Days Following Vaccination and 12 more. Started Jan 2024; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT06237049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237049.